‒ Q4 2024 Net Revenue of $31.2mm; 2024 Net Revenue of $43.5mm ‒ ‒ Q4 Net Income of $13.5mm and Adjusted EBITDA of $15.3mm ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the fourth quarter and full year ended December 31, 2024 a ...

CorMedix Inc. CRMD will release its fourth-quarter financial results, before the opening bell, on Tuesday, March 25.Analysts expect the Berkeley Heights, New Jersey-based company to report quarterly earnings at 14 cents per share, versus a year-ago loss of 26 cents per share in the year-ago period. CorMedix projects quarterly revenue of $28.34 million, according to data from Benzinga Pro.On Jan. 21, CorMedix disclosed that it has engaged with WSI PBG to promote DefenCath® to healthcare providers in faciliti ...

Core Insights - CorMedix Inc. is set to report its financial results for Q4 and the full year of 2024 on March 25, 2025, before market opening [1] - The company will host a corporate update conference call at 8:30 AM ET on the same day [2] Company Overview - CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases [3] - The company's lead product, DefenCath® (taurolidine and heparin), received FDA approval on November 15, 2023, and was commercially launched in inpatient settings in April 2024 and outpatient settings in July 2024 [3] - CorMedix plans to commence clinical studies in adult Total Parenteral Nutrition (TPN) patients and pediatric hemodialysis (HD) patients in 2025, and aims to develop DefenCath as a catheter lock solution for other therapeutic areas [3]

Core Insights - CorMedix Inc. has engaged WSI PBG to promote its product DefenCath to healthcare providers in facilities operated by the Department of Veterans Affairs and other federal facilities, aiming to enhance access for approximately 40,000 veterans with end-stage renal disease [1][2] Company Overview - CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases, with its lead product DefenCath (taurolidine and heparin) approved by the FDA on November 15, 2023 [3] - The company launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024, and plans to commence clinical studies in adult Total Parenteral Nutrition patients and pediatric hemodialysis patient populations in 2025 [3] Collaboration Details - The collaboration with WSI PBG leverages their expertise in navigating the VA and federal facilities, focusing on access, procurement processes, and regulations to meet the unique needs of federal healthcare systems [2] - Joe Todisco, CEO of CorMedix, expressed excitement about the collaboration, highlighting WSI PBG's understanding of the federal healthcare landscape to improve access to DefenCath for veterans and other beneficiaries [3]

Shares of CorMedix (CRMD) rose nearly 30% on Tuesday after management announced fourth-quarter and full-year 2024 preliminary sales figures.CorMedix’s Preliminary Sales Figures Beat EstimatesCorMedix reported preliminary net revenues of nearly $31 million for the fourth quarter of 2024. This unaudited figure significantly beat the Zacks Consensus Estimate of $21.5 million. Based on these figures, management expects adjusted EBITDA for the quarter to exceed $12 million.For the full year, management reported ...

‒ Q4 2024 Unaudited Net Revenue of Approximately $31mm ‒ ‒ FY 2024 Unaudited Net Revenue of Approximately $43mm ‒ ‒ Expects Q4 Adjusted EBITDA to Exceed $12mm ‒ BERKELEY HEIGHTS, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces its preliminary unaudited fourth quarter results and provides an update on its business. These include the fol ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is CorMedix (CRMD) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.CorMedix is a member of the Medical sector. This group includes 1020 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank considers 16 different sector groups ...

BERKELEY HEIGHTS, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced it will be added to the Nasdaq Biotechnology Index (NASDAQ:NBI) (the "NBI"). CorMedix's addition to the NBI will become effective prior to the market open on Monday, December 23, 2024. The NBI is designed to track the performance of a set of securities listed on The NASDA ...

BERKELEY HEIGHTS, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today highlights key policy changes from CMS that benefit hemodialysis patients. Yesterday, the Centers for Medicare & Medicaid Services (CMS) and the Center for Medicare and Medicaid Innovation (CMMI) released important policy updates that will broaden the access of Medicare patients m ...

CorMedix (CRMD) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Since ...